Senior Director, Early Differentiation and Pipeline (EDAP) Lead, Hematology & Oncology at Bristol-Myers Squibb

Princeton, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, OncologyIndustries

Requirements

Strategic leadership within the Worldwide Medical organization, accountable to Early Asset (EA) Development teams
Expertise in interpreting evolving pre-clinical and clinical data to support development plans
Ability to develop sustainable Integrated Evidence Plans (IEP)
Experience engaging with Thought Leaders (TLs, researchers, and clinicians) during pre-Proof of Concept (POC) phase
Knowledge of advancing scientific narratives, early phase research, and competitive landscape
Capability to leverage insights from patient journeys for clinically differentiated compound strategies
Proficiency in communicating and presenting EA portfolio to internal and external partners/customers
Matrix leadership across internal networks (Commercial, R&D, Medical, & Access)

Responsibilities

Develop and execute medical differentiation plans for assigned compounds across 4 domains: Insight gathering and integration; Evidence generation; Medical Communications; Patient Journey
Serve as a critical partner to Early Asset Development Program Leads, Clinical Development Leads, HO Medical/Commercial teams, and Translational Medicine as a core member of early GPTs to ensure medical readiness and deliver objectives/milestones
Act as primary source of Medical accountability for a set of early assets with matrix management across internal networks
Ensure development of a clearly differentiated Target Product Profile (TPP) for each early asset
Own Integrated Evidence Plans (IEP) to complement data generation with Early Drug Development, evaluate IST/ITT/strategic collaboration proposals, including medical biomarker and Translational Medicine components
Develop innovative Early Asset internal and external medical education presentations, programs, and training
Partner with external Thought Leaders on an ongoing basis to gain medical advice on Early Asset strategies, informing asset decision-making and portfolio tradeoffs
Drive early signal detection and accelerate IEP-Lite innovative data generation by engaging with top-tier research institutions worldwide in collaborations

Skills

Oncology

Hematology

Medical Strategy

Translational Medicine

Integrated Evidence Plan

Thought Leader Engagement

Pre-clinical Data

Clinical Data

Early Development

Pipeline Strategy

Scientific Narrative

Competitive Landscape Analysis

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free